Please login to the form below

Not currently logged in
Email:
Password:

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

Novartis  

Novartis's recently approved biosimilar of Amgen's cancer side effects drug has been blocked from sale in the US.

An appeals court is stopping the sale of the Neupogen biosimilar - a drug used to prevent infections in cancer patients - after rejecting a lower court decision that denied an injunction request from Amgen, the original drug's manufacturer. 

The US Court of Appeals for the Federal Circuit is now saying that the injunction could take effect while Amgen's appeal is pending - oral arguments on the appeal have been set for June 3.

In a statement, Amgen said it is pleased with the ruling while Novartis said it looks forward to a “prompt resolution” of the appeal so it can launch its drug “in the near future”.

Novartis' drug has been patented under the name Zarxio and contains the same active ingredient as Neupogen - a product that makes around $1.2bn a year.

When the drug is launched it will become the first biosimilar to be sold in the US. In 2010, President Barack Obama's healthcare reforms allowed the use of biosimilars in the country - drugs that are bioequivalent to original medicines, but which require some R&D as they involve creating living tissue.

Biosimilars have been on the market since 2006 in Europe but the US is much further behind in its regulatory pathway. 

The global biosimilar market is expected to make large savings to payers for biologics, with each product expected to be around 20-50% cheaper that the original drug. Novartis has not yet disclosed the intended US price for Zarxio.

The FDA approved Zarxio in March for the same five conditions for which Neupogen is used among cancer patients undergoing various treatments.

Article by
Ben Adams

8th May 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...